Literature DB >> 31471291

Entrectinib OK'd for Cancers with NTRK Fusions, NSCLC.

.   

Abstract

The FDA has approved entrectinib for patients with any solid tumor bearing NTRK fusions, making it the second TRK inhibitor to receive a tissue-agnostic approval; larotrectinib was the first. How the drugs compare to each other remains unknown. Entrectinib was also approved to treat metastatic non-small cell lung cancer with ROS1 rearrangements. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31471291     DOI： 10.1158/2159-8290.CD-NB2019-101

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

Review 1.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers.

Authors:  Angelina T Regua; Noah R Aguayo; Sara Abu Jalboush; Daniel L Doheny; Sara G Manore; Dongqin Zhu; Grace L Wong; Austin Arrigo; Calvin J Wagner; Yang Yu; Alexandra Thomas; Michael D Chan; Jimmy Ruiz; Guangxu Jin; Roy Strowd; Peiqing Sun; Jiayuh Lin; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

Review 3.  The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample.

Authors:  Jeffrey F Krane; Edmund S Cibas; Mayumi Endo; Ellen Marqusee; Mimi I Hu; Christian E Nasr; Steven G Waguespack; Lori J Wirth; Richard T Kloos
Journal:  Cancer Cytopathol       Date:  2020-06-16       Impact factor: 5.284

Review 4.  Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.

Authors:  Eleanor L Atkinson; Jessica Iegre; Paul D Brear; Elizabeth A Zhabina; Marko Hyvönen; David R Spring
Journal:  Molecules       Date:  2021-03-31       Impact factor: 4.411

5.  Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.

Authors:  Mimi I Hu; Steven G Waguespack; Chrysoula Dosiou; Paul W Ladenson; Masha J Livhits; Lori J Wirth; Peter M Sadow; Jeffrey F Krane; Brendan C Stack; Mark E Zafereo; Syed Z Ali; Steven P Weitzman; Yangyang Hao; Joshua E Babiarz; Giulia C Kennedy; Richard T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

6.  Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.

Authors:  Yiming Zhao; Shuyuan Wang; Zhengyu Yang; Yu Dong; Yanan Wang; Lele Zhang; Hai Hu; Baohui Han
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.